Details of the Drug Combination

General Information of Drug Combination (ID: DC2L9IN)

Drug Combination Name
AG-881 Venglustat
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs AG-881   DMIE1WY Venglustat   DMLPEZS
N.A. N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 25.556
Bliss Independence Score: 39.186
Loewe Additivity Score: 8.568
LHighest Single Agent (HSA) Score: 7.018

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of AG-881
Disease Entry ICD 11 Status REF
Glioma 2A00.0 Phase 3 [2]
Acute myeloid leukaemia 2A60 Phase 1 [3]
AG-881 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Isocitrate dehydrogenase (IDH) TTDTWV0 IDHC_HUMAN; IDHP_HUMAN; IDH3A_HUMAN; IDH3B_HUMAN; IDH3G_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Venglustat
Disease Entry ICD 11 Status REF
Fabry disease 5C56.01 Phase 2 [4]
Parkinson disease 8A00.0 Phase 2 [5]
Gaucher disease 5C56.0Y Phase 1 [6]
Venglustat Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ceramide glucosyltransferase (UGCG) TTPHEX3 CEGT_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT04164901) Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036945)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)